Geovax Labs (Geovax Labs) Float Percentage Of Total Shares Outstanding : 98.34% (As of May. 14, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Geovax Labs Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Geovax Labs's float shares is 2.27 Mil. Geovax Labs's total shares outstanding is 2.31 Mil. Geovax Labs's float percentage of total shares outstanding is 98.34%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Geovax Labs's Insider Ownership is 82.20%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Geovax Labs's Institutional Ownership is 1.25%.

Geovax Labs Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Geovax Labs's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	2.27	/	2.31
	=	98.34%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geovax Labs (Geovax Labs) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Geovax Labs Inc (NAS:GOVX) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

E8L:Germany E8L:Germany

Address

1900 Lake Park Drive, Suite 380, Smyrna, GA, USA, 30080

Website

https://www.geovax.com

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors.

Executives

Mckee Kelly T. Jr.	officer: Chief Medical Officer	233 VALLEY MEADOW DRIVE, CHAPEL HILL NC 27516
David A Dodd	director	C/O SEROLOGICALS CORP, 5565 SPALDING DR, NORCROSS GA 30092
Mark Reynolds	officer: Chief Financial Officer	TWO BALA PLAZA, SUITE 300, PHILADELPHIA PA 19004
Jayne Morgan	director	1900 LAKE PARK DRIVE, SUITE 380, SMYRNA GA 30080
Randal D Chase	director	28 GEORGIA COURT, RICHMOND HILL A6 L4E ON7
Nicole Lemerond	director	3 MURRAY HILL ROAD, SCARSDALE NY 10583
John W. Sharkey	officer: VP, Business Development	16857 E. SAGUARO BLVD., FOUNTAIN HILLS AZ 85268
Dean G Kollintzas	director	1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Spencer John N Jr	director	2859 PACES FERRY RD, STE 1000, ATLANTA GA 30339
Robert T Mcnally	director
Farshad Guirakhoo	officer: Sr VP, Research & Development	39 CHESTNUT STREET, MELROSE MA 02176
Steven S. Antebi	director	10550 FONTENELLE WAY, LOS ANGELES CA 90077
Harriet L Robinson	other: Chair, Scientific Adv Brd	1256 BRIARCLIFF ROAD N.E., EMTECH BIO SUITE 500, ATLANTA GA 30306
Mark J Newman	officer: VP, Research & Development	1900 LAKE PARK DR, SUITE 380, SMYRNA GA 30080
Peter M Tsolinas	director	123 JOAN DRIVE, BARRINGTON IL 60010